Transcript Case- control - Malaria Consortium

Monitoring coverage, safety, efficacy and
impact of SMC
KAMPALA PARTNERS MEETING 18 -20 TH JANUARY 2016
Plan of monitoring activities
Selection SMC areas and
quantification
SMC
SMC
Population surveys for
molecular markers
2014
2015
2016
2017
Coverage surveys
Malaria sentinel surveillance
Case- control
Case- control
Molecular markers
in clinical cases
Targetted spontaneous reporting of adverse drug reactions
Follow-up of SAEs
2018
ACCESS-SMC Research partners
UCAD
Jean Louis Ndiaye
Abdoulaye Diallo
MRC
Kalifa Bojang
Serign Ceesay
IRSS
Jean Bosco Ouedraogo
Issaka Zongo
GANU
Kovana Marcel Loua
MRTC
Alassane Dicko
Issaka Sagara
Abdoulaye Djimde
CERMES
Ibrahim Laminou
EPICENTRE
Matt Coldiron
Rebecca Grais
Aime Makimere
Tony Eloike
Sonny Ogboi
(JEDIMA)
CSSI
Daugla Doumagoum
Jean Pierre Gami
Musa Kana
(Kaduna State University)
Core
Team
Instit.
Place
Name
Role
Email
LSHTM
LSHTM
LSHTM
London
London
London
Paul Milligan
Manuela Claite
Chantelle Thomas
Coordination, + any queries
Admin, finance
Admin, finance
[email protected]
[email protected]
[email protected]
UCAD
UCAD
WHO/TDR
Dakar
Dakar
Geneva
Jean Louis NDiaye
Abdoulaye Diallo
Corinne Merle
Coordination. WARN. PNLP/NMCP
Niger, Chad, Guinea, Gambia
Coordination; Safety monitoring/PV
[email protected]
[email protected]
[email protected]
LSHTM
London
Matt Cairns
Mapping and quantification. Survey sampling. Data
analysis. Modelling.
[email protected]
LSHTM
London
Paul Snell
Data capture; Databases; Data sharing; Tablet PCs;
questionnaires; Web access; Data archiving
[email protected]
LSHTM
LSHTM
LSHTM
London
London
London
Colin Sutherland
Khalid Beshir
Julian M-Karugaba
Drug resistance, lab methods. Head of lab.
Lab methods, sample shipment
Lab, PCR
[email protected]
[email protected]
[email protected]
Collaborators
Pharmacovigilance
Centre Anti-Poison de Maroc and WHO Collaborating Centre for PV
TDR
WHO Safety of Medicines Department
WHO Collaborating Centre for PV
PNLP Senegal
Rabat
Geneva
Geneva
Accra
Dakar
Rachida Souleymani
Corinne Merle, Christine Halleux, Piero Olliaro
Shanti Pal, Noha Iessa
Alex Dodoo
Ibrahima Diallo
Drug resistance:
WWARN Oxford
WHO Antimalarial Efficacy and Response Geneva
Philippe Guerin
Pascal Ringwald
SMC:
MMV Geneva
WARN/CARN SMC Group Dakar
WHO-GMP Geneva
MERG
Andre
Claude Emile, Marie-Reine, Hadiza, Balla, Jean Louis, Philippe
Peter Olumesi
A Noor
Coverage survey
% children who received 0,1,2,3,4 treatments
Reasons for missed treatments
Adherence to daily dose, reasons for missed doses, for the most recent SMC treatment
Perceived side effects
Treatments outside age range (% of 6-yr-olds who were treated)
Education and socio-economic status of the caregiver
Mode of delivery
Time and costs to get SMC
Bednet coverage (all age groups)
Rapid assessment
How did you hear about SMC and about dates of SMC this month
Caregiver’s understanding of key messages about SMC and how to administer doses
Adherence to daily doses, check of left-over medication
Side effects: incidence of symptoms, and symptom severity
Case control study
Efficacy of SMC treatments (% reduction in malaria cases, duration of protection)
◦ Malaria confirmed by microscopy
◦ Adherence to doses
◦ Confounding factors (bednet use, socio-economic status)
Markers of drug resistance in early failures
Survey to measure prevalence of molecular
markers of resistance to SMC drugs
Prevalence of infection by PCR, in children and in older individuals
Prevalence of markers of resistance to SP and AQ in children <5yrs and in individuals too old to
have received SMC
(Genetic factors related to drug side effects)
Bednet use and treatment seeking behaviour to see if any change after SMC
Any SMC and antimalarial treatments received (effect on prevalence of markers of resistance)
Follow-up of severe cases of adverse
drug reactions
Causality:
◦
◦
◦
◦
timing and dosage of all medications received in relation to onset of symptoms
description of the symptoms
underlying medical conditions
treatment providers since onset of symptoms
Duration of hospitalisation
Patient outcome
Check appropriate patient care, follow-up, reimbursement
Blood sample for genetics
Sentinel surveillance
Incidence of outpatient malaria, inpatient malaria, in all age groups
All cases tested or treated for malaria (% treatments based on RDT)
◦ Date, age, gender, symptoms, diagnostic, treatment
◦ Dates of SMC treatment of malaria cases in children
Used RDT cassettes retained for analysis of molecular markers or resistance
Reminders about PV